Phase II Study of the Anti-Cytotoxic T-Lymphocyte–Associated Antigen 4 Monoclonal Antibody, Tremelimumab, in Patients With Refractory Metastatic Colorectal Cancer
- 20 July 2010
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (21), 3485-3490
- https://doi.org/10.1200/jco.2010.28.3994
Abstract
Purpose Safety and efficacy of tremelimumab (CP-675,206), a fully human anti-cytotoxic T-lymphocyte–associated antigen 4 (CTLA4) monoclonal antibody, were assessed in patients with treatment-refractory colorectal cancer. Patients and Methods A single-arm, multicenter, phase II trial was conducted in patients with Eastern Cooperative Oncology Group performance status ≤ 1 and measurable colorectal carcinoma for whom standard treatments for metastatic disease had failed. Patients received 15 mg/kg tremelimumab intravenously every 90 days until progression. Primary end point was objective response status (per Response Evaluation Criteria in Solid Tumors). Secondary end points included safety, duration of response, progression-free survival, and overall survival. Results Forty-seven patients who had received extensive prior therapies (all had received fluoropyrimidines, oxaliplatin, and irinotecan; most [91%] had also received cetuximab) were treated. Grade 3/4 treatment-related adverse events (AEs) were diarrhea (n = 5; 11%), ulcerative colitis (n = 1; 2%), fatigue (n = 1; 2%), autoimmune thrombocytopenia (n = 1; 2%), and hypokalemia (n = 1; 2%), which resolved spontaneously or with interventions. Six patients discontinued because of an AE; two were considered treatment related. Of 45 response-evaluable patients, 44 did not reach second dose (43 progressive disease; one discontinuation). Twenty-one patients (45%) lived ≥ 180 days after enrollment. One patient (2%; 90% CI, < 1% to 10%) had a stable pelvic mass and substantial regression in an adrenal mass (partial response). This patient received five tremelimumab doses; response duration was 6 months (enrollment to disease progression, 15 months). Conclusion Tremelimumab did not demonstrate clinically meaningful single-agent activity in this patient population, although the number of survivors at 6 months and the one patient with confirmed partial response are potentially interesting. Further study of tremelimumab in combination with other agents may be warranted.Keywords
This publication has 12 references indexed in Scilit:
- Phase II Trial of Tremelimumab (CP-675,206) in Patients with Advanced Refractory or Relapsed MelanomaClinical Cancer Research, 2010
- Ipilimumab: controversies in its development, utility and autoimmune adverse eventsCancer Immunology, Immunotherapy, 2009
- Immunostimulatory monoclonal antibodies for cancer therapyNature Reviews Cancer, 2007
- Active Specific Immunotherapy with Autologous Tumor cell vaccines for Stage II Colon Cancer: Logistics, Efficacy, Safety and Immunological PharmacodynamicsHuman Vaccines, 2006
- Chemo-Immunotherapy of Metastatic Colorectal Carcinoma With Gemcitabine Plus FOLFOX 4 Followed by Subcutaneous Granulocyte Macrophage Colony-Stimulating Factor and Interleukin-2 Induces Strong Immunologic and Antitumor Activity in Metastatic Colon Cancer PatientsJournal of Clinical Oncology, 2005
- Antitumor Activity in Melanoma and Anti-Self Responses in a Phase I Trial With the Anti-Cytotoxic T Lymphocyte–Associated Antigen 4 Monoclonal Antibody CP-675,206Journal of Clinical Oncology, 2005
- Human CTLA4 knock-in mice unravel the quantitative link between tumor immunity and autoimmunity induced by anti–CTLA-4 antibodiesBlood, 2005
- Enhancement of Antitumor Immunity by CTLA-4 BlockadeScience, 1996
- A Randomized Study of Low-Dose Subcutaneous lnterleukin-2 Plus Melatonin versus Supportive Care Alone in Metastatic Colorectal Cancer Patients Progressing under 5-Fluorouracil and FolatesOncology, 1995
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958